APELOA(SZ:000739)2021-08-18 16:00Financial Performance - The company's operating revenue for the reporting period was ¥4,277,125,693.79, representing a 7.15% increase compared to ¥3,991,768,060.82 in the same period last year[12]. - The net profit attributable to shareholders of the listed company was ¥553,408,494.47, which is a 28.86% increase from ¥429,471,282.68 in the previous year[12]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥503,398,008.59, up 25.43% from ¥401,338,011.97 in the same period last year[12]. - The basic earnings per share for the reporting period was ¥0.4696, reflecting a 28.87% increase compared to ¥0.3644 in the previous year[12]. - The total assets at the end of the reporting period were ¥8,435,811,838.42, which is a 12.56% increase from ¥7,494,787,957.34 at the end of the previous year[12]. - The net assets attributable to shareholders of the listed company were ¥4,657,745,885.88, representing a 6.08% increase from ¥4,390,675,233.32 at the end of the previous year[12]. - The net cash flow from operating activities was ¥323,169,178.27, showing a decrease of 49.90% compared to ¥645,027,102.57 in the same period last year[12]. - The weighted average return on net assets was 12.10%, an increase of 1.23% from 10.87% in the previous year[12]. Business Segments - The CDMO business generated revenue of 720.82 million yuan, up 30.65% year-on-year, with a gross margin of 43.32%, an increase of 2.55 percentage points[17]. - The total number of CDMO clients increased by 51.0% year-on-year, with 355 quoted projects, a 157% increase, and 250 ongoing projects, a 71% increase[17]. - The raw material intermediate business reported revenue of 3.137 billion yuan, a growth of 3.90% year-on-year, with a gross margin of 23.02%[18]. - The formulation business achieved revenue of 402.19 million yuan, a year-on-year increase of 9.46%, with a gross margin of 64.60%, up 10.65 percentage points[19]. Strategic Initiatives - The company is focusing on strategic goals of "refining raw materials, strengthening CDMO, and optimizing formulations" to navigate the complex external environment[17]. - The company is actively expanding its product pipeline, with several new products approved and entering the market, including the injection of cefoperazone[19]. - The company plans to increase its CDMO R&D investment, with a goal of expanding its Shanghai R&D center from 130 to 500 personnel by 2024[24]. - The company is adapting to regulatory changes and increasing environmental standards, which are impacting the pharmaceutical industry[19]. Market Overview - The global pharmaceutical market size is expected to reach $1.45 trillion in 2021 and $1.6395 trillion by 2024, with a compound annual growth rate (CAGR) of 4.4% from 2019 to 2024[20]. - China's pharmaceutical industry has become a major global player, with raw material drug exports accounting for approximately 20% of the global market share[21]. - The CDMO industry in China reached over 40 billion yuan in 2019, growing at approximately 19%, significantly outpacing the global CDMO market growth rate of about 13%[23]. Research and Development - The company has completed 4 domestic formulation registrations and 2 API registrations during the reporting period, along with 7 new DMF submissions for raw materials[25]. - The company has a total of 745 R&D personnel, including 144 with master's degrees and 45 with doctoral degrees[24]. - The global pipeline of new drugs reached 16,000 in 2019, reflecting a year-on-year growth of approximately 6%, supporting the rapid development of the CDMO business[22]. - The company has submitted 7 invention patent applications and received 5 invention patent grants in the first half of the year, with a total of 123 effective patents by the end of the reporting period[25]. Environmental and Social Responsibility - The company has invested in 12 sets of RTO waste gas treatment facilities, achieving a total organic waste gas treatment capacity of 350,000 m³/h[28]. - The company has implemented a three-year action plan for EHS, focusing on VOCs governance and ensuring the normal operation of pollution prevention facilities[28]. - The company has established a comprehensive emergency response plan for safety and environmental incidents, with all subsidiaries having set up EHS management organizations[58]. - The company has actively engaged in social responsibility initiatives, including charity activities and support for employees in need[62]. Financial Management - The company's financial expenses increased significantly by 356.11% due to exchange losses, compared to a gain in the previous year[32]. - The company aims to become a leading technology-driven pharmaceutical manufacturer in China, supported by its "344" quality management model[31]. - The company has established a global marketing network covering over 70 countries and regions, with a strong presence in North America, Europe, and Asia[31]. - The company has passed multiple international certifications, including WHO, FDA, and EU EDQM, enhancing its credibility in the global market[31]. Shareholder Information - The total share capital as of the last trading day before disclosure was 1,178,523,492 shares[12]. - The company has implemented an employee stock ownership plan, acquiring 32,664,016 shares, which represents 2.77% of the total share capital, for a total transaction amount of ¥260,658,847.68[49]. - The largest shareholder, Hengdian Group Holdings Co., Ltd., holds 28.08% of the shares, amounting to 330,941,729 shares[90]. Compliance and Governance - The company adheres to the accounting standards set by the Ministry of Finance and the China Securities Regulatory Commission, ensuring the financial statements reflect true and complete financial conditions[138]. - The company has no significant doubts regarding its ability to continue as a going concern for the next 12 months[136]. - The company has not faced any administrative penalties for environmental issues during the reporting period[59]. - The company has not engaged in any major litigation or arbitration matters during the reporting period[65].